Related by context. All words. (Click for frequent words.) 67 pCR 67 biochemical recurrence 66 postoperative mortality 66 serum PSA 66 locoregional recurrence 65 PSA nadir 65 preoperative PSA 65 troponin T 65 advanced adenoma 64 specific antigen PSA 64 serum testosterone 64 #.#ng/ml 64 postoperative complication 64 undergoing radical prostatectomy 64 serum urate levels 64 biochemical relapse 63 nondiabetic patients 63 5-fluorouracil/leucovorin 63 postoperative infection 63 % CI #.#-#.# [003] 63 pT3 63 glycated hemoglobin levels 63 HER2 expression 63 perioperative mortality 63 colorectal adenoma 63 advanced adenomas 63 adrenalectomy 62 postoperative pulmonary 62 serum phosphate 62 clinically localized prostate 62 radical prostatectomy RP 62 posttransplant 62 elevated CRP 62 femoral neck fracture 62 radioiodine therapy 62 intracerebral haemorrhage 62 PSADT 62 underwent resection 62 endometrial carcinoma 62 total thyroidectomy 62 HBeAg seroconversion 61 platelet reactivity 61 alanine aminotransferase ALT 61 prostate cancer CaP 61 resected pancreatic cancer 61 SUVmax 61 femoral shaft fracture 61 CIN3 61 neutrophil counts 61 CIN2 + 61 extracapsular extension 61 PCa 61 azoospermia 61 dose ionizing radiation 61 malignant neoplasm 61 ovarian malignancy 61 ruptured aneurysms 61 OGTT 61 glomerular filtration 61 underwent coronary angiography 61 EpCAM expression 61 axillary node 61 rebleeding 61 carotid stenosis 61 pT2 61 advanced neoplasia 60 distant metastasis 60 preoperative chemotherapy 60 eosinophil count 60 nodal metastases 60 intact parathyroid hormone 60 lactate dehydrogenase 60 systolic dysfunction 60 peritoneal cancer 60 thyroglobulin 60 postoperative chemotherapy 60 LV dysfunction 60 HIV HCV coinfected 60 CVD mortality 60 recurrent VTE 60 locoregional 60 PCA3 scores 60 lymph node involvement 60 complete cytogenetic response 60 postoperative morbidity 60 serum estradiol 60 histologic subtype 60 EUS FNA 60 euthyroid 60 biopsy Gleason 60 cytoreductive surgery 60 hip BMD 60 EBRT 60 lymphocytosis 60 R0 resection 60 urolithiasis 60 aspartate aminotransferase 60 interferon ribavirin 60 lymphocyte count 60 multivariable adjusted 60 N telopeptide 60 micrometastasis 60 sustained virological response 60 elevated ALT 60 coronary stenosis 60 colorectal carcinoma 59 HNSCC 59 serum calcium levels 59 obstructive CAD 59 wound dehiscence 59 serum calcium 59 NMIBC 59 detectable HCV RNA 59 coronary calcification 59 prostate cancer PCa 59 pelvic lymphadenectomy 59 androgen suppression 59 graft occlusion 59 leukocyte count 59 cerebral infarction 59 mL/min/#.# m 2 59 distant metastases 59 urinary N telopeptide 59 asymptomatic carotid stenosis 59 undergone radical prostatectomy 59 prostate carcinoma 59 periprocedural 59 serum uric acid 59 obstructive coronary artery 59 pretest probability 59 nondiabetic 59 baseline LDH 59 liver histology 59 liver resection 59 axillary node dissection 59 pancreatic resection 59 plasma homocysteine 59 axillary dissection 59 perioperative morbidity 59 mutated KRAS 59 serum prostate 59 FOLFOX4 59 antigen PSA 59 serum testosterone levels 59 lumbar disk herniation 59 % Confidence Interval 59 colorectal polyp 59 invasive ductal 59 seropositivity 59 renal cell carcinomas 59 postoperative complications 59 CR nPR 59 atypical hyperplasia 58 postop 58 invasive aspergillosis 58 HGPIN 58 neurologic complications 58 precancerous cervical 58 receiving VICTRELIS 58 PASI scores 58 B7 H3 58 ejection fractions 58 monoclonal gammopathy 58 seminoma 58 response pCR 58 noncardiac 58 epithelial ovarian cancer 58 contralateral breast 58 GISTs 58 vaginal hysterectomy 58 acromegalic patients 58 Radical prostatectomy 58 atherogenic dyslipidemia 58 clinically detectable 58 HbA1C levels 58 cytologic 58 creatinine levels 58 serum IGF 58 intravesical therapy 58 neurodevelopmental impairment 58 HbA1C 58 SLNB 58 operable breast cancer 58 BRCA2 mutation carriers 58 ALND 58 incomplete revascularization 58 Prostate Specific Antigen PSA 58 albumin excretion rate 58 debulking surgery 58 endometrial thickness 58 malignant lesions 58 univariate analyzes 58 serous ovarian cancer 58 BRCA1 mutation carriers 58 T1a 58 Postoperatively 58 serum homocysteine 58 clinically insignificant 58 colorectal neoplasia 58 locoregional disease 58 carcinoid tumor 58 confidence intervals CIs 58 CR CRu 58 urothelial cancer 58 plain radiographs 58 node metastases 58 histological subtype 58 MMSE score 58 serum cortisol 58 adjuvant radiotherapy 58 tumor recurrence 58 MGUS 58 glycated hemoglobin HbA1c 58 symptomatic aortic stenosis 58 CIN3 + 58 lymph node metastasis 58 autonomic dysfunction 58 urine NGAL 58 androgen suppression therapy 58 metachronous 58 neutrophil count 58 definite stent thrombosis 58 angiographic restenosis 58 hemoglobin Hb 58 HOMA IR 58 binary restenosis 58 radical retropubic prostatectomy 58 F FDG PET 58 cardiac troponin T 58 NNRTI resistance 58 univariate analysis 58 endometrial hyperplasia 57 adjuvant radiation 57 subtrochanteric 57 recurrent ischemic stroke 57 acute aortic dissection 57 KRAS mutations occur 57 chemo radiotherapy 57 serum ALT 57 relapsed MM 57 elevated LDH 57 vertebral fracture 57 urate levels 57 ASCUS 57 Ishak fibrosis score 57 complete cytogenetic 57 #mmHg [001] 57 haemorrhagic stroke 57 Partial Responses 57 perioperatively 57 ductal cancer 57 recurrent venous thromboembolism 57 thyroid nodules 57 lymph node metastases 57 cGy 57 Viral load 57 allogeneic HSCT 57 gastric adenocarcinoma 57 Hip fracture 57 HER2 overexpression 57 serum urate 57 dysglycemia 57 nonfasting triglyceride levels 57 postprocedure 57 chemoembolization 57 microscopic hematuria 57 HoLEP 57 underwent radical prostatectomy 57 CCyR 57 polyp recurrence 57 adenoma recurrence 57 lobular cancer 57 tHcy 57 reinfarction 57 CP CPPS 57 peritoneal carcinomatosis 57 angiographically 57 MACCE 57 rheumatoid factor 57 MetS 57 intraobserver 57 TNF antagonist 57 perioperative complications 57 HbA 1c levels 57 hepatorenal syndrome 57 periprosthetic infection 57 haematologic 57 metastatic lesions 57 albumin excretion 57 multivariable analysis 57 tPSA 57 arterial thickening 57 hematuria 57 IV bisphosphonates 57 transferrin saturation 57 chronic prostatitis 57 serum sodium 57 radical prostatectomy 57 neurodevelopmental outcomes 57 D dimer 57 aminotransferases 57 Tumor shrinkage 57 Prostatitis 57 hemoglobin A1c HbA1c 57 serum TSH 57 pathologic fractures 57 oral Hycamtin 57 tipranavir r 57 hemoglobin A1c levels 57 nodal metastasis 57 serum concentrations 57 low expressors 57 ischemic lesions 57 cerebral angiography 57 pelvic radiotherapy 57 TRUS biopsy 57 testicular tumors 57 lymphadenectomy 57 femoral neck fractures 57 gastrectomy 57 PCNSL 57 cytogenetic responses 57 thromboembolic 57 adenoma 57 skeletal metastases 57 chlamydial infection 57 serum sodium levels 57 axillary lymph nodes 57 serum glucose 57 CDI recurrence 57 paricalcitol 57 paraprotein 56 creatine kinase 56 postoperative radiotherapy 56 Doxil ® 56 androgen ablation 56 seminal vesicle invasion 56 ICD implantation 56 A1c levels 56 subclinical hyperthyroidism 56 experienced virologic failure 56 adenomatous 56 ductal breast cancer 56 atypia 56 upper gastrointestinal bleeding 56 virologic response 56 plasma cortisol 56 interobserver reliability 56 CC genotype 56 highest tertile 56 serum creatinine levels 56 differentiated thyroid 56 thrombotic complications 56 EGFR mutation status 56 neoadjuvant chemotherapy 56 PSA velocity 56 remission CR 56 hematologic toxicity 56 elevated uric acid 56 serum selenium 56 SHBG levels 56 bladder carcinoma 56 cranial irradiation 56 testosterone supplementation 56 severe neutropenia 56 liver transplant recipients 56 P = .# 56 lumbar spine BMD 56 fetuin 56 invasive lobular 56 varicocele 56 mucinous 56 colorectal neoplasms 56 serum HCV RNA 56 lowest tertile 56 ng dL 56 Adjuvant chemotherapy 56 neoadjuvant therapy 56 plasma folate 56 renal tumors 56 hematopoietic cancers 56 reintervention 56 hemorrhagic complications 56 sensitivity specificity 56 hemodilution 56 antithymocyte globulin 56 chorioamnionitis 56 recurrent glioblastoma multiforme 56 nonmetastatic prostate cancer 56 apo B 56 sleeve lobectomy 56 baseline HbA1c 56 cTnT 56 % CI #.#-#.# [008] 56 severe exacerbations 56 myeloid leukemia 56 mesotheliomas 56 nonfatal MI 56 primary aldosteronism 56 osteoporotic fracture 56 nonalcoholic steatohepatitis NASH 56 thymectomy 56 Prostate specific antigen 56 neoadjuvant radiation 56 latent celiac disease 56 spontaneous circulation ROSC 56 postoperative infections 56 confidence interval #.#-#.# 56 adnexal mass 56 primary hyperparathyroidism 56 nonvertebral fractures 56 tracer uptake 56 intima media thickness 56 hydroxyvitamin D levels 56 nondiabetics 56 BRCA mutation 56 arterial thromboembolic events 56 carotid plaques 56 postoperative AF 56 hemodialysis patients 56 neoplasias 56 androgen deprivation 56 urinary bladder cancer 56 serum PTH 56 grade squamous intraepithelial 56 orchiectomy 56 amenorrhoea 56 mCi 56 LVEF 56 TKAs 56 p = .# [002] 56 esophageal carcinoma 56 pulmonary dysfunction 56 mmol l 56 prostate specific antigen 56 sentinel node 56 metastatic testicular cancer 56 elevated creatinine 56 liver metastasis 56 papillary carcinoma 56 FluCAM arm 56 cardiac troponin 56 antibody titer 56 LVNC 56 neurologic progression 56 tumor histology 56 penetrance 56 Univariate analysis 56 metastatic lung cancer 56 % CI #.#-#.# [007] 56 homocysteine concentrations 56 hypofractionated radiation 56 chronic GVHD 56 oral clodronate 56 recurrent UTI 56 precancerous cervical lesions 56 underwent liver transplantation 56 hip resurfacing arthroplasty 56 prednisone prednisolone 56 T1c 55 subclinical disease 55 p = NS 55 multivariable analyzes 55 T1DM 55 TURP 55 Partial Response 55 lymphocyte counts 55 melanoma lesions 55 elevated LDL cholesterol 55 ovarian carcinoma 55 cytogenic 55 elevated triglyceride levels 55 mIU L 55 bioavailable testosterone 55 gallstone disease 55 procalcitonin 55 nocturnal hypoglycaemia 55 beta blocker therapy 55 nonischemic 55 thyrotropin 55 tumor resection 55 cTnT levels 55 renal carcinoma 55 sentinel nodes 55 lobular carcinoma 55 virologic failure 55 metastatic malignant melanoma 55 nonoperative treatment 55 cytoreduction 55 subclinical hypothyroidism 55 lung resection 55 abnormal mammogram 55 smoldering myeloma 55 thromboembolic complications 55 hsCRP levels 55 prostate cancer CRPC 55 lumbar disc herniation 55 colorectal cancer liver metastases 55 SGOT 55 heterozygotes 55 colon rectal 55 grade cervical intraepithelial 55 external beam radiotherapy 55 dose clopidogrel 55 BRCA mutations 55 obstructive coronary 55 ADPKD 55 cerebral oxygen saturation 55 prolonged QT interval 55 stage IIIb IV 55 Legg Calvé Perthes disease 55 HbA 1c 55 mutated K ras 55 enterovirus infection 55 EDSS scores 55 thyroidectomy 55 recurrent ischemia 55 EBV infection 55 histopathologic examination 55 atypical ductal hyperplasia 55 Prostate Specific Antigen 55 serum thyroglobulin 55 Hurthle cell 55 serum albumin 55 subclinical atherosclerosis 55 malignant neoplasms 55 pancreatic adenocarcinoma 55 NYHA functional class 55 POAG 55 thyrotropin levels 55 oncologic outcomes 55 prostate biopsy 55 nonvertebral fracture 55 CMV infection 55 Kaplan Meier 55 sonographically guided 55 FDG uptake 55 radiographic progression 55 bacterial prostatitis 55 blood glucose concentrations 55 axillary lymph node 55 silent ischemia 55 gadolinium enhanced 55 #mg dose [002] 55 node dissection 55 nephron sparing surgery 55 interobserver agreement 55 imipenem 55 postoperative atrial fibrillation 55 HSCT 55 placebo dexamethasone 55 lung resections 55 malignant pleural mesothelioma 55 prostate walnut 55 intravenous bisphosphonates 55 PSA prostate 55 undergo prostate biopsy 55 comorbid illnesses 55 triacylglycerol concentrations 55 carotid IMT 55 estrogen receptor ER 55 prospectively defined 55 sUA 55 Ebstein anomaly 55 Rectal cancer 55 hepatectomy 55 SGRQ 55 bilateral oophorectomy 55 Acute Myeloid Leukaemia AML 55 adrenal function 55 IV NSCLC 55 PPCM 55 severe hypoglycaemia 55 microalbumin test 55 polycystic ovary syndrome PCOS 55 recurrent myocardial infarction 55 subfertility 55 μmol L 55 mg kg dose 55 infarct size 55 depressive symptomatology 55 PHPT 55 gestational hypertension 55 symptomatic intracerebral hemorrhage 55 hypogonadal 55 systolic function 55 cervical intraepithelial neoplasia 55 symptomatic VTE 55 tertile 55 micrometastases 55 seminomas 55 MADRS score 55 Median survival 55 diabetes mellitus DM 55 adjuvant cisplatin 55 Hazard Ratio 55 virological response 55 serum lipid levels 55 evaluable subjects 55 plasma glucose levels 55 Cystectomy 55 neutropenic sepsis 55 prostatectomy 55 elevated hsCRP 55 coronary blockages 55 hormone receptor negative 55 lung metastasis 55 tricuspid regurgitation 55 needle aspiration 55 tissue oxygenation 55 metastatic lymph nodes 55 hamartomas 55 dose atorvastatin 55 imatinib therapy 55 DEXA scans 55 cytogenetic response 55 Hb A1C 55 median PFS 55 stent stenosis 55 DAS# CRP 55 8 OHdG 55 simvastatin ezetimibe 55 myeloablative 55 sentinel lymph node biopsy 55 oral allopurinol 54 plasma uric acid 54 testicular germ cell 54 salivary cortisol 54 severe hypoglycemic 54 myocardial viability 54 noncarriers 54 liver biopsies 54 recurrent DVT 54 cervical lesions 54 nonmalignant 54 cortisol concentrations 54 adenoma detection 54 PSA kinetics 54 colorectal liver metastases 54 paragangliomas 54 renal artery stenosis 54 neurologic deficits 54 adenomatous polyps 54 breast carcinoma 54 urothelial carcinoma 54 helical CT 54 Tumors shrank 54 microalbuminuria 54 serum triglyceride levels 54 rechallenge 54 urethral stricture 54 spontaneous bacterial peritonitis 54 nonsmall cell lung cancer 54 relapsed AML 54 arteriography 54 anthracycline taxane 54 cirrhotic patients 54 lymph node dissection 54 sustained virologic response 54 parkinsonian symptoms 54 CTEPH 54 unresectable tumors 54 FDG-PET/CT 54 carotid artery blockage 54 invasive candidiasis 54 renal scarring 54 ischemic cardiomyopathy 54 fasting insulin 54 intestinal metaplasia 54 multivariate adjustment 54 maximal aerobic capacity 54 achieving PASI 54 Flu Cy 54 fragility fracture 54 anti JCV antibodies 54 hippocampal atrophy 54 urine dipstick 54 nonadherence 54 lymphopenia 54 salpingo oophorectomy 54 serum aminotransferase levels 54 aortic atherosclerosis 54 hemoglobin concentrations 54 Subgroup analyzes 54 antiangiogenic therapy 54 β blockers 54 severe periodontitis 54 macroalbuminuria 54 distal colon cancer 54 chemoradiation therapy 54 orchitis 54 fasting glucose levels 54 endometrial biopsy 54 Adjuvant therapy 54 coagulation abnormalities 54 triglyceride concentrations 54 proximal colon 54 hyperacute 54 decompensated cirrhosis 54 isolated systolic hypertension 54 NovoTTF 54 fructose diet 54 Stent thrombosis 54 median survivals 54 Circulating tumor cells 54 adrenocortical 54 anastomotic leak 54 aminotransferase levels 54 radicular pain 54 MALT lymphoma 54 cutaneous melanoma 54 choriocarcinoma 54 prostate adenocarcinoma 54 percutaneous biopsy 54 NT proBNP 54 radical cystectomy 54 achieved ACR# 54 corticosteroid dose 54 colonoscopic 54 premalignant lesions 54 histologically confirmed 54 Chronic pancreatitis 54 Kaplan Meier estimates 54 extracolonic findings 54 artery stenosis 54 fibrinolysis 54 parathyroidectomy 54 polyp detection 54 urine albumin 54 APOE e4 54 elevated homocysteine 54 serum vitamin D 54 grade dysplasia 54 interquartile range 54 hepatic metastases 54 thyroid carcinoma 54 #mmHg [002] 54 nadroparin 54 transrectal ultrasound guided 54 inhospital mortality 54 varicoceles 54 urinary oxalate 54 mm Hg systolic 54 femoral shaft fractures 54 hepatic cirrhosis 54 serum LDL cholesterol 54 ACR Pedi 54 acute cholecystitis 54 left ventricular systolic 54 endoscopic remission 54 varices 54 graft dysfunction 54 surgically resectable 54 microvascular complications 54 intravenous cyclophosphamide 54 neurodevelopmental outcome 54 variceal hemorrhage 54 surgical debulking 54 antioxidant supplementation 54 circulating EPCs 54 hemodynamically unstable 54 abnormal Pap test 54 peginterferon 54 neutropaenia 54 preeclamptic 54 ERCC1 54 anthracycline chemotherapy 54 multivariate analyzes 54 prostate specific 54 adjuvant tamoxifen 54 curative resection 54 chromosomal mutations 54 mammographically 54 μg dL 54 SLN biopsy 54 Kaplan Meier analysis 54 bowel polyps 54 atheroma volume 54 familial ALS 54 CMV infections 54 osteopenic 54 thymoma 54 Hcy 54 IL#B 54 cancerdefine 54 leukaemias 54 viral titers 54 transfusion syndrome 54 clinicopathological features 54 invasive coronary angiography 54 radical nephrectomy 54 invasive fungal infection 54 lung nodule 54 p# activation 54 papillary thyroid carcinoma 54 GH deficiency 54 radiochemotherapy 54 renal dysfunction 54 postoperative delirium 54 anti Mullerian hormone 54 metastatic prostate 54 trabeculectomy 54 urine cytology 54 rituximab monotherapy 54 univariate 54 cystectomy 54 abnormal cytology 54 silent myocardial ischemia 54 retransplantation 54 TEAEs 54 hepatic fibrosis 54 abnormal mammograms 54 serum BDNF 54 rimonabant #mg 54 prospectively stratified 53 serum triglyceride 53 aneurysm rupture 53 ipsilateral stroke 53 ventricular tachyarrhythmia 53 cardiac dysfunction 53 deep venous thromboses 53 cecal intubation 53 mammographic density 53 hypertensives 53 progression TTP 53 aromatase inhibitor therapy 53 fluvastatin 53 neoplasm 53 precursor lesions 53 prostate TURP 53 prognostic variables 53 brachial blood 53 elevated fasting glucose 53 ipsilateral breast 53 colorectal adenomas 53 albuminuria 53 cytological 53 serum parathyroid hormone 53 #F FDG 53 benign nodules 53 BRCA mutation carriers 53 paclitaxel eluting stents 53 prostate cancer HRPC 53 sarcomatoid 53 GnRH agonist 53 completely resected 53 oblimersen 53 mineral density 53 metastatic lesion 53 nonunions 53 ECG abnormalities 53 breast endometrial 53 Postoperative complications 53 K ras mutations 53 bone scintigraphy 53 precancerous spots 53 Androgen deprivation therapy 53 preserved ejection fraction 53 abdominal hysterectomy 53 adriamycin 53 TT genotype 53 Heavy menstrual bleeding 53 spinal metastases 53 Adenomas 53 epithelial tumors 53 epididymal 53 chest radiograph 53 noncancerous prostate 53 serum creatinine 53 nonmelanoma skin cancers 53 curability 53 bony metastases 53 radiographic findings 53 clinicopathological 53 nmol L 53 highest quintile 53 esophagogastroduodenoscopy 53 urinary protein 53 DVT PE 53 foveal thickness 53 fasting triglyceride levels 53 virological suppression 53 calcaneal fractures 53 atherothrombotic disease 53 colorectal cancer incidence 53 irinotecan chemotherapy 53 Kaplan Meier estimate 53 neurologic outcomes 53 glycosylated hemoglobin 53 serum clusterin levels 53 log# reduction 53 placenta accreta 53 ximelagatran 53 histologic 53 achieved CCyR 53 Prognostic factors 53 lymph node biopsies 53 IGFBP 3 53 lobular breast cancer 53 peri procedural 53 Uterine cancer 53 T2DM 53 esophageal perforation 53 atherosclerotic progression 53 bowel resection 53 NGAL 53 leukemia AML 53 NMP# 53 aortic insufficiency 53 coronary artery calcification 53 reoperations 53 pg ml 53 undergoing hysterectomy 53 postsurgery 53 genotype 1b 53 nonmetastatic 53 clinically evaluable patients 53 creatinine ratio 53 sFlt 1 53 incidentalomas 53 lopinavir r arm 53 serum ferritin 53 MYCN amplification 53 GnRH agonists 53 IU ml 53 plasma triglycerides 53 serum magnesium 53 esophageal gastric 53 Brain metastases 53 ml kg 53 clodronate 53 morphometric vertebral fractures 53 VUR 53 thyroid stimulating hormone 53 bronchogenic carcinoma 53 del 5q 53 colon resection 53 temporal lobectomy 53 metastatic gastric 53 normothermia 53 acute lymphoblastic 53 EXJADE 53 basal cell carcinoma BCC 53 urate lowering therapy 53 gastric carcinoma 53 bezafibrate 53 hepatitis C genotype 53 annualized relapse 53 pelvic lymph nodes 53 ejection fraction EF 53 undergoing CABG 53 tibial plateau fractures 53 undergo radical prostatectomy 53 ventricular arrhythmia 53 glycemia 53 nonalcoholic steatohepatitis 53 benign polyps 53 bone marrow aspiration 53 p# Shc 53 colorectal metastases 53 testicular cancers 53 microalbumin 53 CD# mAb 53 serum IgE 53 elevated bilirubin 53 gastroduodenal 53 pelvic malignancies 53 heterotopic ossification 53 LHRH agonists 53 mcg albinterferon alfa 2b 53 handgrip strength 53 antiphospholipid syndrome 53 response CCyR 53 cranial radiation 53 tenecteplase 53 esophagectomy 53 perfusion defects 53 de novo AML 53 naïve HCV 53 CI -#.# 53 XL# administered orally 53 neoadjuvant 53 ductal carcinomas 53 undergoing coronary angiography 53 pelvic ultrasound 53 vestibular dysfunction 53 appendiceal 53 PNH patients 53 ACR# response 53 Bone density 53 gemcitabine carboplatin 53 fibroadenomas 53 endophthalmitis 53 transplantation HCT 53 recurrent prostate cancer 53 radiologically 53 patients evaluable 53 breast carcinomas 53 revascularization procedure